Entertainment Industry Agreement Reflects Real-World Adoption of Humanoid Robotics Technology Across Education, Healthcare, Hospitality, and Customer Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.

娱乐行业协议反映了人形机器人技术在教育、医疗、酒店业和客户互动领域的实际采用；Onconetix 最近签署了一项最终协议，以收购 Realbotix Corp. 的子公司 Realbotix LLC。

CINCINNATI, Ohio, Aug. 06, 2026 (GLOBE NEWSWIRE) --

俄亥俄州辛辛那提，2026年8月6日（环球新闻社）--

Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix’s previously announced pending acquisition.

Onconetix, Inc.（纳斯达克股票代码：ONCO）（“Onconetix”或“公司”）现提供由Realbotix Corp.（Realbotix LLC的母公司，“Realbotix”）发布的新闻稿摘要，Realbotix是Onconetix此前宣布的待完成收购的目标公司。

Realbotix has entered into an agreement with a recognized streaming platform to feature one of its humanoid robots as a robotic character in an upcoming episode of a popular Emmy-awarded television series. Onconetix is sharing this development with its shareholders as it relates to Realbotix, the target of the pending acquisition..

Realbotix 已与一家知名流媒体平台达成协议，将其一款人形机器人作为机器人角色植入一部即将播出的热门艾美奖获奖电视剧集中。Onconetix 就此进展向股东进行通报，因该事项涉及其待收购目标公司 Realbotix。

The entertainment industry agreement adds another market in which Realbotix is active, alongside existing deployments in education, healthcare, hospitality, and customer engagement. These sectors are part of a broader market opportunity for humanoid robotics that span many sectors, including research applications and additional industries..

娱乐业协议为Realbotix增添了另一个活跃市场，与其在教育、医疗、酒店业和客户互动领域的现有部署并列。这些领域构成了人形机器人更广泛的市场机遇的一部分，该机遇涵盖众多领域，包括研究应用及其他行业。

Realbotix’s robots are designed to operate as physical embodiments of AI systems while also supporting digital counterparts accessible through mobile devices, desktop platforms, and robotic interfaces, allowing the technology to extend across both physical robotics and scalable software experiences..

Realbotix 的机器人旨在作为人工智能系统的物理实体运行，同时支持可通过移动设备、桌面平台和机器人接口访问的数字对应物，从而使该技术能够延伸至物理机器人和可扩展的软件体验两大领域。

As previously announced on February 12, 2026, Onconetix entered into a definitive share exchange agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC, a wholly-owned subsidiary of Realbotix Corp., in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which is anticipated to occur in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions..

正如2026年2月12日此前宣布的那样，Onconetix公司签订了一份最终的股份交换协议，以全股票交易方式收购Realbotix Corp.的全资子公司Realbotix LLC的100%已发行和流通股权。预计合并后的公司将在交易完成后在纳斯达克上市，该交易预计将于2026年下半年完成，前提是获得Onconetix股东批准、必要的监管批准以及其他交割条件。

This communication includes information regarding Realbotix, a company that Onconetix has agreed to acquire, and is being provided for informational purposes only. Investors are cautioned not to place undue reliance on forward-looking or projected information.

本沟通文件包含有关Realbotix的信息，Onconetix已同意收购该公司，该信息仅供资讯参考之用。提醒投资者勿过度依赖前瞻性或预测性信息。

About Onconetix, Inc.

关于Onconetix公司

Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S.

Onconetix, Inc.（纳斯达克股票代码：ONCO）是一家处于商业化阶段的生物技术公司，专注于创新肿瘤解决方案的研发与商业化。Onconetix 拥有 Proclarix®，这是一种由 Proteomedix 最初开发的前列腺癌体外诊断检测产品，已根据欧盟体外诊断医疗器械法规（IVDR）获准在欧盟销售，公司预计该产品将在美国市场推出。

as a lab developed test through its license agreement with Labcorp. For more information, visit .

作为通过其与Labcorp的许可协议开发的实验室检测项目。欲了解更多信息，请访问。

www.onconetix.com

www.onconetix.com

.

。

About Realbotix LLC

关于 Realbotix LLC

Realbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending acquisition. Realbotix LLC develops AI-powered humanoid robots designed for human interaction across enterprise and consumer environments. Manufactured in the United States, Realbotix’s patented AI and robotics technologies enable lifelike expressions, motion, vision, and social engagement.

Realbotix LLC 是 Realbotix Corp.（TSX-V: XBOT；法兰克福：76M0.F；OTC: XBOTF）的全资子公司，也是 Onconetix 待完成收购的目标公司。Realbotix LLC 开发由人工智能驱动的人形机器人，旨在用于企业和消费者环境中的人际互动。Realbotix 的产品在美国制造，其拥有专利的人工智能和机器人技术能够实现逼真的表情、动作、视觉和社交互动能力。

For more information, visit .

更多信息，请访问。

www.realbotix.ai

www.realbotix.ai

.

。

Additional Information and Where to Find It

附加信息及查询途径

In connection with the proposed transaction between Realbotix and Onconetix, Onconetix intends to file with the SEC a Registration Statement on Form S-4 (the “Registration Statement”) to register the common stock to be issued by Onconetix in connection with the proposed transaction. The Registration Statement will include a proxy statement of Onconetix and a prospectus of Onconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and Onconetix may file with the SEC other relevant documents concerning the proposed transaction.

就Realbotix与Onconetix之间拟议的交易而言，Onconetix打算向美国证券交易委员会（SEC）提交一份S-4表格注册声明（“注册声明”），以登记Onconetix因该拟议交易而将发行的普通股。该注册声明将包括Onconetix的委托书和招股说明书（“委托书/招股说明书”），并且Realbotix和Onconetix均可能向SEC提交与该拟议交易相关的其他文件。

After the Registration Statement is declared effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Onconetix to seek their approval of the proposed transaction. This is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or any other relevant documents that Realbotix or Onconetix has filed or will file with the SEC.

在注册声明生效之后，最终的代理声明/招股说明书将发送给Onconetix的股东，以寻求他们对拟议交易的批准。这不能替代Realbotix或Onconetix已向或即将向美国证券交易委员会（SEC）提交的注册声明、代理声明/招股说明书或任何其他相关文件。

BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE PROPOSED TRANSACTION, AND RELATED MATTERS..

在作出任何投票或投资决策之前，Onconetix 的投资者和股东被敦促仔细并完整地阅读与拟议交易相关的注册声明和代理声明/招股说明书，以及任何其他相关文件，并在这些文件的修订或补充文件可用时及时阅读，因为这些文件将包含有关 Realbotix、Onconetix、拟议交易及相关事项的重要信息。

A copy of the Registration Statement, Proxy Statement/Prospectus, as well as other relevant documents filed by Realbotix and Onconetix with the SEC, may be obtained free of charge, when they become available, at the SEC’s website at

注册声明、代理声明/招股说明书，以及 Realbotix 和 Onconetix 向美国证券交易委员会（SEC）提交的其他相关文件，可在其公布后于美国证券交易委员会网站免费获取，网址为

www.sec.gov

www.sec.gov

. The information on Realbotix or Onconetix’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

Realbotix 或 Onconetix 各自网站上的信息不构成、也不应被视为本沟通文件的一部分，亦不被纳入两家公司向美国证券交易委员会（SEC）提交的其他文件中。

Participants in the Solicitation

招标参与者

Realbotix, Onconetix and certain of their respective directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Onconetix, their ownership of Onconetix common stock, and Onconetix’s transactions with related persons is set forth in the 10-K, as filed with the SEC on March 13, 2026, and other documents that may be filed from time to time with the SEC.

Realbotix、Onconetix 以及它们各自的某些董事、高级管理人员和员工可能被视为在与拟议交易相关的代理权征集活动中的参与者。关于 Onconetix 的董事和高级管理人员、其对 Onconetix 普通股的所有权以及 Onconetix 与关联方之间的交易的信息，载于 Onconetix 于 2026 年 3 月 13 日向美国证券交易委员会（SEC）提交的 10-K 表格年度报告，以及可能不时向 SEC 提交的其他文件中。

Additional information about the directors and executive officers of Realbotix and Onconetix and other persons who may be deemed to be participants in the solicitation of stockholders of Onconetix in connection with the proposed transaction and a description of their direct and indirect interests will be included in the Proxy Statement/Prospectus related to the proposed transaction or other relevant materials, which will be filed with the SEC.

关于Realbotix和Onconetix的董事及高级管理人员，以及可能被视为参与就拟议交易向Onconetix股东进行征集的其他人员的更多信息，及其直接和间接利益的描述，将包含在与拟议交易相关的代理声明/招股说明书或其他相关材料中，这些文件将提交给美国证券交易委员会（SEC）。

These documents may be obtained free of charge, when they become available, at the SEC’s website at .

这些文件在发布后，可在美国证券交易委员会（SEC）网站免费获取。

www.sec.gov

www.sec.gov

and from Onconetix using the sources indicated above.

以及从 Onconetix 公司获取，使用上述指明的来源。

No Offer or Solicitation

无要约或招揽

This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

本沟通文件仅供信息参考，无意构成也不构成出售任何证券的要约或购买或出售任何证券的要约邀请，亦不构成对任何代理权、投票或批准的征集；在任何司法管辖区，若根据该司法管辖区的证券法在注册或资格认定之前进行此类要约、征集或销售属违法行为，则不得在该司法管辖区进行任何证券销售。

No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act..

不得通过招股说明书以外的任何方式发行证券，该招股说明书须符合《证券法》第10条的要求，或在豁免于《证券法》注册要求的交易中进行。

Forward-Looking Statements

前瞻性陈述

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others.

本新闻稿中的某些陈述属于1995年《私人证券诉讼改革法》所定义的“前瞻性陈述”。这些陈述可以通过使用诸如“预期”、“相信”、“预测”、“估计”、“期望”和“打算”等前瞻性词汇来识别。

These forward-looking statements (including, without limitation, the anticipated benefits and opportunities that may be generated by the proposed transaction described herein) are based on Onconetix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.

这些前瞻性陈述（包括但不限于本文所述拟议交易可能产生的预期效益和机会）基于Onconetix当前的预期，实际结果可能存在重大差异。有许多因素可能导致实际事件与这些前瞻性陈述所指示的情况存在重大差异。

These factors include, but are not limited to, the occurrence of any event, change, or other circumstances that could give rise to the right of one or both of the parties to terminate the share exchange agreement; the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not satisfied on a timely basis or at all, including the failure to timely obtain stockholder approval for the proposed transaction from Onconetix’s stockholders, if at all; risks related to Onconetix’s continued listing on Nasdaq until closing of the proposed transaction; the outcome of any legal proceedings that may be instituted against Realbotix, Onconetix, or the combined company; the possibility that the anticipated benefits of the proposed transaction are not realized when expected or at all; the possibility that the vision, goals, and trajectory of the combined company are not timely achieved or realized or achieved or realized at all; the possibility that the proposed transaction may be more expensive or take longer to complete than ant.

这些因素包括但不限于：发生任何可能导致一方或双方有权终止股份交换协议的事件、变化或其他情况；由于交割条件未能及时或完全得到满足（包括未能及时获得Onconetix股东对拟议交易的批准，如果最终能获得的话），导致拟议交易无法按预期完成或根本无法完成的可能性；与Onconetix在拟议交易完成前继续在纳斯达克上市相关的风险；可能对Realbotix、Onconetix或合并后的公司提起的任何法律诉讼的结果；拟议交易的预期效益未能按预期实现或根本未能实现的可能性；合并后公司的愿景、目标和战略轨迹未能及时实现或根本未能实现的可能性；以及拟议交易的成本可能高于预期或完成时间可能长于预期的可能性。

Investor and Media Contact:

投资者与媒体联系人：

Onconetix, Inc.

Onconetix 公司

201 E. Fifth Street, Suite 1900

东五街201号，1900室

Cincinnati, OH 45202

俄亥俄州辛辛那提，邮编 45202

Phone: (513) 620-4101

电话：(513) 620-4101

Email:

电子邮件：

investors@onconetix.com

investors@onconetix.com